DK346789D0 - NEUTRALIZATION OF IN VIVO AND IN VITRO TOXIC PROPERTIES OF TNF-ALPHA WITH MONOCLONAL ANTIBODIES AND DERIVATIVE DRAGMENTS - Google Patents

NEUTRALIZATION OF IN VIVO AND IN VITRO TOXIC PROPERTIES OF TNF-ALPHA WITH MONOCLONAL ANTIBODIES AND DERIVATIVE DRAGMENTS

Info

Publication number
DK346789D0
DK346789D0 DK346789A DK346789A DK346789D0 DK 346789 D0 DK346789 D0 DK 346789D0 DK 346789 A DK346789 A DK 346789A DK 346789 A DK346789 A DK 346789A DK 346789 D0 DK346789 D0 DK 346789D0
Authority
DK
Denmark
Prior art keywords
dragments
tnf
neutralization
vivo
alpha
Prior art date
Application number
DK346789A
Other languages
Danish (da)
Other versions
DK346789A (en
Inventor
Achim Moeller
Franz Emling
Manfred Kurfuerst
Thomas Meyer
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of DK346789D0 publication Critical patent/DK346789D0/en
Publication of DK346789A publication Critical patent/DK346789A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK346789A 1988-07-14 1989-07-13 NEUTRALIZATION OF IN VIVO AND IN VITRO TOXIC PROPERTIES OF TNF-ALPHA WITH MONOCLONAL ANTIBODIES AND DERIVATIVE DRAGMENTS DK346789A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3823804A DE3823804A1 (en) 1988-07-14 1988-07-14 NEUTRALIZATION OF THE TOXIC PROPERTIES OF TNF- (ALPHA) IN VITRO AND VIVO BY MONOCLONAL ANTIBODIES AND THE FRAGMENTS DERIVED FROM THEM

Publications (2)

Publication Number Publication Date
DK346789D0 true DK346789D0 (en) 1989-07-13
DK346789A DK346789A (en) 1990-01-15

Family

ID=6358617

Family Applications (1)

Application Number Title Priority Date Filing Date
DK346789A DK346789A (en) 1988-07-14 1989-07-13 NEUTRALIZATION OF IN VIVO AND IN VITRO TOXIC PROPERTIES OF TNF-ALPHA WITH MONOCLONAL ANTIBODIES AND DERIVATIVE DRAGMENTS

Country Status (6)

Country Link
EP (1) EP0350690A3 (en)
JP (1) JPH02109994A (en)
DE (1) DE3823804A1 (en)
DK (1) DK346789A (en)
FI (1) FI893428A (en)
ZA (1) ZA895325B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
ES2156859T5 (en) * 1991-03-18 2008-03-16 New York University SPECIFIC MONOCLONAL AND CHEMICAL ANTIBODIES FOR THE HUMAN TUMOR NECROSIS FACTOR.
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
ES2108460T3 (en) * 1993-06-03 1997-12-16 Therapeutic Antibodies Inc FRAGMENTS OF ANTIBODIES IN THERAPEUTICS.
EP0846169B1 (en) * 1995-08-04 2003-03-19 Lek, Tovarna Farmacevtskih in Kemicnih Izdelkov, D.D. MONOCLONAL ANTIBODIES AGAINST SOLUBLE TNF-ALPHA RECEPTORS p55 and p75 AS WELL AS AGAINST TNF-ALPHA AND ITS ANALOGUES
GB9517538D0 (en) * 1995-08-26 1995-10-25 Therapeutic Antibodies Inc Production and therapeutic combinations, of antibodies
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
CN101980722A (en) * 2007-08-08 2011-02-23 雅培制药有限公司 Compositions and methods for crystallizing antibodies
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JP2020506916A (en) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド Anti-TNF antibodies, compositions and methods for the treatment of active psoriatic arthritis
CA3052578A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3631229A1 (en) * 1986-09-13 1988-03-24 Basf Ag MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE
EP0355067A1 (en) * 1988-08-19 1990-02-21 Celltech Limited Pharmaceutical products for anti-neoplastic therapy

Also Published As

Publication number Publication date
EP0350690A3 (en) 1990-07-04
FI893428A0 (en) 1989-07-14
ZA895325B (en) 1991-04-24
DE3823804A1 (en) 1990-01-18
EP0350690A2 (en) 1990-01-17
FI893428A (en) 1990-01-15
DK346789A (en) 1990-01-15
JPH02109994A (en) 1990-04-23

Similar Documents

Publication Publication Date Title
DK346789A (en) NEUTRALIZATION OF IN VIVO AND IN VITRO TOXIC PROPERTIES OF TNF-ALPHA WITH MONOCLONAL ANTIBODIES AND DERIVATIVE DRAGMENTS
DK0748197T4 (en) Absorbent article with extendable waistband of structural elastic-like and with several zones
MX9100529A (en) SUBSTITUTED DERIVATIVES OF OXAZOLIDINDIONA AND PROCESS FOR ITS PREPARATION
MX9101793A (en) DERIVATIVES OF TIAZOLIDINDIONA AND PROCEDURE FOR ITS PREPARATION
DK0941121T3 (en) Stable lyophilized pharmaceutical preparations of mono- or polyclonal antibodies
DK149990A (en) FAMILY OF MODIFIED ANTIBODIES WITH HIGH EFFICIENCY FOR CANCER TREATMENT
NO177057C (en) Process for the preparation of pyrrolopyrimidines and their intermediates
NO915017L (en) MONOCLONAL ANTIBODIES AND PROCEDURES FOR THEIR PREPARATION
ES2018594B3 (en) PIECE OF WATCHES AND PROCEDURE FOR ITS REALIZATION
NO923878L (en) PROCEDURE AND MATERIAL FOR REPAIR OF FLOWMANTS
MX9100742A (en) PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR ITS PREPARATION
MX9100811A (en) INDOLONAFTIRIDINES AND PROCEDURE FOR ITS PREPARATION
DK96088A (en) APPLICATION FOR GRAZING AND SIMILAR GROWTH
MX9100367A (en) DERIVATIVES OF HETEROARILCETONE AND PROCEDURE FOR ITS PREPARATION
MX174227B (en) COMPOSITION OF ANHYDRA MIXTURES OF PARACHLOROMETAXILENOL AND METHOD FOR ITS PREPARATION
DK579089D0 (en) PURE-INHIBITIVE URINARY DERIVATIVES OF DIPEPTIDES, THEIR PREPARATION AND USE
DK1031565T3 (en) Novel crystals of depsipeptide derivative and process for their preparation
PT799039E (en) USING AMINOPURIN ANIVIRAL AGENTS FOR THE TREATMENT AND PROPHYLAXIA OF LATENT INFECTIONS BY HERPES VIRUS
MX9101814A (en) SUBSTITUTED DERIVATIVES OF AMINO ACID AMIDES AND PROCEDURE FOR THEIR OBTAINING
MX9101654A (en) TRIAZOLOPYRIDAZINE DERIVATIVES AND PREPARATION PROCEDURE
MX9203512A (en) NEUTRALIZATION OF THE IN VITRO AND LIVE TOXIC PROPERTIES OF TNF-ALPHA THROUGH MONOCLONAL ANTIBODIES AND THE FRAGMENTS DERIVED FROM THEM.
MX9100388A (en) DERIVATIVES OF CARBOXIMETILCICLOPROPANO AND PROCEDURE FOR ITS PREPARATION
MX9101663A (en) REINFORCED THERMOPLASTIC COMPONENTS FOR USE IN THE MANUFACTURE OF OPHTHALMIC LENSES AND METHODS FOR PREPARING THESE COMPONENTS
MX9100676A (en) PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES AND THE PROCESS FOR THEIR PREPARATION
DK59687A (en) PROCEDURE AND AGREEMENT FOR THE DELIVERY OF MATERIAL CHICKENS BETWEEN TWO MOVING MOVING HARDERING BODIES

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment